FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1835676912> ?p ?o ?g. }

• W1835676912 endingPage "200" @default.
• W1835676912 startingPage "194" @default.
• W1835676912 abstract "Abstract Aim The objective of the study was to compare the efficacy and safety of oral paricalcitol with oral calcitriol for treating secondary hyperparathyroidism. Methods We conducted the first multicenter open‐labelled parallel group randomized controlled trial in 66 patients on dialysis. Patients were randomized to paricalcitol or calcitriol at a 3:1 dose ratio and adjusted to maintain intact parathyroid hormone ( iPTH ) level between 150–300 pg/mL, serum calcium ≤2.74 mmol/L and calcium‐phosphate product ≤5.63 mmol 2 /L 2 . The primary end point was the proportion of patients who achieved >30% reduction in iPTH . Results At 24 weeks, 22 (61.1%) patients in the paricalcitol and 22 (73.3%) in the calcitriol group had achieved the primary end‐point ( P ‐value = 0.29). The cumulative proportion of patients who achieved the end‐point at 6 weeks, 12 weeks and 24 weeks were 50%, 80.6% and 86.1%, respectively, in paricalcitol and 53.3%, 86.7% and 86.7%, respectively, in the calcitriol group ( P ‐value = 0.67). Median time to the end‐point was 6 weeks in both groups. There were no significant differences in iPTH level at any time during the study. The median reduction in iPTH at 24 weeks was 48.4% in the paricalcitol group and 41.9% in the calcitriol group ( P ‐value = 0.6). The median maximal iPTH reduction was 77.1% (paricalcitol) and 83.7% (calcitriol), P ‐value = 0.3. Serum calcium and incidence of hypercalcaemia did not differ between groups. 16.7% of patients in both groups had at least one episode of hypercalcaemia (serum calcium >2.74 mmol/L). Other adverse events were similar between groups. Conclusion Our study suggests that oral paricalcitol has similar efficacy and safety to oral calcitriol." @default.
• W1835676912 created "2016-06-24" @default.
• W1835676912 creator A5005130591 @default.
• W1835676912 creator A5022488557 @default.
• W1835676912 creator A5028896642 @default.
• W1835676912 creator A5032835237 @default.
• W1835676912 creator A5035507396 @default.
• W1835676912 creator A5037960635 @default.
• W1835676912 creator A5040442260 @default.
• W1835676912 creator A5053526866 @default.
• W1835676912 creator A5060736977 @default.
• W1835676912 creator A5062552652 @default.
• W1835676912 creator A5066753586 @default.
• W1835676912 creator A5068439644 @default.
• W1835676912 creator A5073925569 @default.
• W1835676912 creator A5079561290 @default.
• W1835676912 creator A5091741648 @default.
• W1835676912 date "2013-02-25" @default.
• W1835676912 modified "2023-10-16" @default.
• W1835676912 title "Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism" @default.
• W1835676912 cites W1958413320 @default.
• W1835676912 cites W1983032812 @default.
• W1835676912 cites W1997341767 @default.
• W1835676912 cites W2023637811 @default.
• W1835676912 cites W2031941775 @default.
• W1835676912 cites W2038986027 @default.
• W1835676912 cites W2041692221 @default.
• W1835676912 cites W2055923382 @default.
• W1835676912 cites W2089374072 @default.
• W1835676912 cites W2338582714 @default.
• W1835676912 doi "https://doi.org/10.1111/nep.12029" @default.
• W1835676912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23311404" @default.
• W1835676912 hasPublicationYear "2013" @default.
• W1835676912 type Work @default.
• W1835676912 sameAs 1835676912 @default.
• W1835676912 citedByCount "21" @default.
• W1835676912 countsByYear W18356769122013 @default.
• W1835676912 countsByYear W18356769122014 @default.
• W1835676912 countsByYear W18356769122015 @default.
• W1835676912 countsByYear W18356769122016 @default.
• W1835676912 countsByYear W18356769122017 @default.
• W1835676912 countsByYear W18356769122018 @default.
• W1835676912 countsByYear W18356769122019 @default.
• W1835676912 countsByYear W18356769122020 @default.
• W1835676912 countsByYear W18356769122021 @default.
• W1835676912 crossrefType "journal-article" @default.
• W1835676912 hasAuthorship W1835676912A5005130591 @default.
• W1835676912 hasAuthorship W1835676912A5022488557 @default.
• W1835676912 hasAuthorship W1835676912A5028896642 @default.
• W1835676912 hasAuthorship W1835676912A5032835237 @default.
• W1835676912 hasAuthorship W1835676912A5035507396 @default.
• W1835676912 hasAuthorship W1835676912A5037960635 @default.
• W1835676912 hasAuthorship W1835676912A5040442260 @default.
• W1835676912 hasAuthorship W1835676912A5053526866 @default.
• W1835676912 hasAuthorship W1835676912A5060736977 @default.
• W1835676912 hasAuthorship W1835676912A5062552652 @default.
• W1835676912 hasAuthorship W1835676912A5066753586 @default.
• W1835676912 hasAuthorship W1835676912A5068439644 @default.
• W1835676912 hasAuthorship W1835676912A5073925569 @default.
• W1835676912 hasAuthorship W1835676912A5079561290 @default.
• W1835676912 hasAuthorship W1835676912A5091741648 @default.
• W1835676912 hasBestOaLocation W18356769121 @default.
• W1835676912 hasConcept C124490489 @default.
• W1835676912 hasConcept C126322002 @default.
• W1835676912 hasConcept C126894567 @default.
• W1835676912 hasConcept C134018914 @default.
• W1835676912 hasConcept C168563851 @default.
• W1835676912 hasConcept C203092338 @default.
• W1835676912 hasConcept C2775945674 @default.
• W1835676912 hasConcept C2776079296 @default.
• W1835676912 hasConcept C2778838027 @default.
• W1835676912 hasConcept C2779524405 @default.
• W1835676912 hasConcept C2779674975 @default.
• W1835676912 hasConcept C2781208988 @default.
• W1835676912 hasConcept C519063684 @default.
• W1835676912 hasConcept C71924100 @default.
• W1835676912 hasConcept C90924648 @default.
• W1835676912 hasConceptScore W1835676912C124490489 @default.
• W1835676912 hasConceptScore W1835676912C126322002 @default.
• W1835676912 hasConceptScore W1835676912C126894567 @default.
• W1835676912 hasConceptScore W1835676912C134018914 @default.
• W1835676912 hasConceptScore W1835676912C168563851 @default.
• W1835676912 hasConceptScore W1835676912C203092338 @default.
• W1835676912 hasConceptScore W1835676912C2775945674 @default.
• W1835676912 hasConceptScore W1835676912C2776079296 @default.
• W1835676912 hasConceptScore W1835676912C2778838027 @default.
• W1835676912 hasConceptScore W1835676912C2779524405 @default.
• W1835676912 hasConceptScore W1835676912C2779674975 @default.
• W1835676912 hasConceptScore W1835676912C2781208988 @default.
• W1835676912 hasConceptScore W1835676912C519063684 @default.
• W1835676912 hasConceptScore W1835676912C71924100 @default.
• W1835676912 hasConceptScore W1835676912C90924648 @default.
• W1835676912 hasIssue "3" @default.
• W1835676912 hasLocation W18356769121 @default.
• W1835676912 hasLocation W18356769122 @default.
• W1835676912 hasOpenAccess W1835676912 @default.
• W1835676912 hasPrimaryLocation W18356769121 @default.
• W1835676912 hasRelatedWork W1984335979 @default.

• next